Loading
A phase 3 trial of APG-157 run by Aveta Biomics, Inc., not yet recruiting.
APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT07667296 by Aveta Biomics, Inc., with 826 participants planned, started 2026-07. Conditions recorded: Head and Neck Cancer, Head and Neck (HNSCC), Oropharyngeal, Oral Cavity, Oral Cavity Carcinoma, Oropharynx Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma. Interventions recorded: APG-157, Surgery, Radiation/Chemotherapy and Radiation/Chemotherapy.
Shares Aveta Biomics, APG-157, Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Aveta Biomics, APG-157, Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Aveta Biomics, APG-157 and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/